Cannabidiol ( DrugBank: Cannabidiol )

18 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	3
8	ハンチントン病	1
13	多発性硬化症／視神経脊髄炎	27
36	表皮水疱症	2
46	悪性関節リウマチ	2
95	自己免疫性肝炎	1
96	クローン病	3
97	潰瘍性大腸炎	3
140	ドラベ症候群	20
144	レノックス・ガストー症候群	18
145	ウエスト症候群	4
156	レット症候群	7
157	スタージ・ウェーバー症候群	2
158	結節性硬化症	8
193	プラダー・ウィリ症候群	3
206	脆弱Ｘ症候群	3
226	間質性膀胱炎（ハンナ型）	1
271	強直性脊椎炎	1

6. パーキンソン病

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-003623-37-GB (EUCTR)	12/02/2020	02/01/2020	CANnabidiol for Parkinson’s Disease Psychosis	CANnabidiol for Parkinson’s Disease Psychosis - CAN-PDP	Parkinson's disease psychosis MedDRA version: 20.0;Level: PT;Classification code 10074835;Term: Parkinson's disease psychosis;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]	Product Name: Cannabidiol Product Code: Cannabidiol INN or Proposed INN: Cannabidiol (CBD)	King's College London	South London and Maudsley NHS Foundation Trust	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	144	Phase 2	United Kingdom
2	NCT03582137 (ClinicalTrials.gov)	September 17, 2018	17/4/2018	A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease	A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease	Parkinson Disease	Drug: Cannabidiol;Other: Placebo	University of Colorado, Denver	Colorado Department of Public Health and Environment	Completed	40 Years	85 Years	All	74	Phase 2	United States
3	NCT02818777 (ClinicalTrials.gov)	October 2016	6/5/2016	A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease	A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease	Parkinson's Disease	Drug: cannabidiol	University of Colorado, Denver	Colorado Department of Public Health and Environment;GW Research Ltd	Completed	40 Years	80 Years	All	13	Phase 2	United States

8. ハンチントン病

臨床試験数 : 229 / 薬物数 : 193 - (DrugBank : 60) / 標的遺伝子数 : 84 - 標的パスウェイ数 : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01502046 (ClinicalTrials.gov)	September 2011	29/12/2011	Neuroprotection by Cannabinoids in Huntington's Disease	A Double Blind, Randomized, Cross Over, Placebo Controlled Phase 2 Clinical Trial to Asses Neuroprotection by Cannabinoids in Huntington's Disease	Huntington's Disease	Drug: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD);Drug: Placebo	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	GW Pharmaceuticals Ltd.	Completed	18 Years	N/A	Both	25	Phase 2	Spain

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05269628 (ClinicalTrials.gov)	March 2022	13/2/2022	Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype	Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain Phenotype	Multiple Sclerosis;Sleep;Pain	Drug: Cannabidiol (CBD);Drug: Tetrahydrocannabinol (THC);Drug: Placebo CBD;Drug: Placebo THC	Tiffany J. Braley, MD, MS	National Center for Complementary and Integrative Health (NCCIH)	Not yet recruiting	18 Years	65 Years	All	166	Phase 2	United States
2	EUCTR2020-004306-58-LT (EUCTR)	28/01/2022	25/11/2021	A study to asses the effects of Nabiximols on spasticity associated with multiple sclerosis.	A randomized double-blind placebo-controlled study of nabiximols in patients with spasticity in multiple sclerosis - RELEASE MSS4	Symptomatic treatment of spasticity in patients with MS MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Nabiximols - Sativex INN or Proposed INN: Tetrahydrocannabinol Botanical Drug Substance (THC BDS) Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: Cannabidiol Botanical Drug Substance (CBD BDS) Other descriptive name: CANNABIDIOL	GW Pharma Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	575	Phase 3	United States;Hungary;Canada;Spain;Lithuania;Bulgaria;United Kingdom;Italy
3	EUCTR2020-003271-18-ES (EUCTR)	01/07/2021	05/07/2021	A trial to test how efficient Nabiximols is for treatment of spacticity in patients with Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis	Symptomatic treatment of spasticity in patients with multiple sclerosis (MS) MedDRA version: 20.0;Level: PT;Classification code 10028335;Term: Muscle spasticity;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sativex 2,7mg/2,5 mg Solucion para pulverizacion bucal Product Name: Nabiximols - Sativex INN or Proposed INN: Tetrahydrocannabinol Botanical Drug Substance (THC BDS) Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: Cannabidiol Botanical Drug Substance (CBD BDS) Other descriptive name: CANNABIDIOL	GW Pharma Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	190	Phase 3	Czechia;Czech Republic;Poland;Belgium;Spain;Australia;United Kingdom;Sweden
4	EUCTR2020-003271-18-CZ (EUCTR)	07/06/2021	07/04/2021	A trial to test how efficient Nabiximols is for treatment of spacticity in patients with Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis	Symptomatic treatment of spasticity in patients with multiple sclerosis (MS) MedDRA version: 20.0;Level: PT;Classification code 10028335;Term: Muscle spasticity;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sativex Oromucosal Spray Product Name: Nabiximols - Sativex INN or Proposed INN: Tetrahydrocannabinol Botanical Drug Substance (THC BDS) Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: Cannabidiol Botanical Drug Substance (CBD BDS) Other descriptive name: CANNABIDIOL	GW Pharma Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	190	Phase 3	Czechia;Czech Republic;Spain;Poland;Belgium;Australia;United Kingdom;Sweden
5	EUCTR2019-002625-29-CZ (EUCTR)	18/05/2021	10/03/2021	A trial to test how efficient Nabiximols is for treatment of spacticity in patients with Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis	Symptomatic treatment of spasticity in patients with multiple sclerosis (MS) MedDRA version: 20.0;Level: PT;Classification code 10028335;Term: Muscle spasticity;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sativex Oromucosal Spray Product Name: Nabiximols - Sativex INN or Proposed INN: Tetrahydrocannabinol Botanical Drug Substance (THC BDS) Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: Cannabidiol Botanical Drug Substance (CBD BDS) Other descriptive name: CANNABIDIOL	GW Pharma Limited	NULL	Not Recruiting			Female: yes Male: yes	104	Phase 3	Czechia;Czech Republic;Poland;United Kingdom
6	EUCTR2019-002623-14-PL (EUCTR)	15/04/2020	21/01/2020	A study to evaluate the efficacy and safety of nabiximols oromucosal spray as add-on therapy in patients with muscle stiffness due to multiple sclerosis	A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients with Spasticity Due to Multiple Sclerosis	Symptomatic relief of spasticity in Multiple Sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Classification code 10028335;Term: Muscle spasticity;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sativex INN or Proposed INN: Tetrahydrocannabinol Botanical Drug Substance (THC BDS) Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: Cannabidiol Botanical Drug Substance (CBD BDS) Other descriptive name: CANNABIDIOL	GW Pharma Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	446	Phase 3	United States;Czechia;Czech Republic;Poland;Romania;United Kingdom
7	EUCTR2019-002623-14-CZ (EUCTR)	17/03/2020	19/12/2019	A study to evaluate the efficacy and safety of nabiximols oromucosal spray as add-on therapy in patients with muscle stiffness due to multiple sclerosis	A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients with Spasticity Due to Multiple Sclerosis	Symptomatic relief of spasticity in Multiple Sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Classification code 10028335;Term: Muscle spasticity;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sativex Oromucosal Spray (non-marketed) INN or Proposed INN: Tetrahydrocannabinol Botanical Drug Substance (THC BDS) Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: Cannabidiol Botanical Drug Substance (CBD BDS) Other descriptive name: CANNABIDIOL	GW Pharma Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	446	Phase 3	United States;Czechia;Czech Republic;Poland;Romania;United Kingdom
8	EUCTR2019-002625-29-GB (EUCTR)	16/03/2020	18/06/2020	A trial to test how efficient Nabiximols is for treatment of spacticity in patients with Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis - Study in MS patient Naïve to treatment with Nabiximols	Symptomatic treatment of spasticity in patients with multiple sclerosis (MS) MedDRA version: 20.0;Level: PT;Classification code 10028335;Term: Muscle spasticity;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sativex Oromucosal Spray Product Name: Sativex Oromucosal Spray INN or Proposed INN: Tetrahydrocannabinol Botanical Drug Substance (THC BDS) Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: Cannabidiol Botanical Drug Substance (CBD BDS) Other descriptive name: CANNABIDIOL	GW Pharma Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 3	Poland;United Kingdom
9	EUCTR2019-002623-14-GB (EUCTR)	24/02/2020	18/03/2020	A study to evaluate the efficacy and safety of nabiximols oromucosal spray as add-on therapy in patients with muscle stiffness due to multiple sclerosis	A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients with Spasticity Due to Multiple Sclerosis - Nabiximols Oromucosal Spray as Add-on Therapy in Patients with MS	Symptomatic relief of spasticity in Multiple Sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Classification code 10028335;Term: Muscle spasticity;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: UK: Sativex Oromucosal Spray Product Name: UK: Sativex Oromucosal Spray INN or Proposed INN: Tetrahydrocannabinol Botanical Drug Substance (THC BDS) Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: Cannabidiol Botanical Drug Substance (CBD BDS) Other descriptive name: CANNABIDIOL	GW Pharma Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	446	Phase 3	United States;Czech Republic;Poland;Romania;United Kingdom
10	EUCTR2019-002625-29-PL (EUCTR)	14/01/2020	21/11/2019	A trial to test how efficient Nabiximols is for treatment of spacticity in patients with Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis	Symptomatic treatment of spasticity in patients with multiple sclerosis (MS) MedDRA version: 20.0;Level: PT;Classification code 10028335;Term: Muscle spasticity;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sativex Oromucosal Spray Product Name: Nabiximols - Sativex INN or Proposed INN: Tetrahydrocannabinol Botanical Drug Substance (THC BDS) Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: Cannabidiol Botanical Drug Substance (CBD BDS) Other descriptive name: CANNABIDIOL	GW Pharma Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 3	Czechia;Czech Republic;Poland;United Kingdom
11	EUCTR2018-002315-98-DK (EUCTR)	06/12/2018	09/07/2018	The effect of cannabis products on nerve pain and muscle stiffness in patients with multiple sclerosis and in patients with spinal cord injury.	The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial - The effect of medical cannabis on neuropathic pain and spasticity in patients with MS and SCI	Central neuropathic pain and spasticity MedDRA version: 20.0;Level: PT;Classification code 10028335;Term: Muscle spasticity;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: LLT;Classification code 10077975;Term: Central neuropathic pain;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol capsule 5 mg Product Code: N/A INN or Proposed INN: Cannabidiol Other descriptive name: CBD Product Name: Dronabinol capsule 2,5 mg Product Code: N/A INN or Proposed INN: DRONABINOL Other descriptive name: THC Product Name: Cannabidiol / Dronabinol capsule 5 mg+2,5 mg Product Code: N/A INN or Proposed INN: DRONABINOL Other descriptive name: THC INN or Proposed INN: Cannabidiol Other descriptive name: CBD	Aarhus Universitetshospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	448	Phase 2	Denmark
12	EUCTR2015-004451-40-AT (EUCTR)	01/03/2016	14/01/2016	SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS	SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICSTHE S A V A N T TRIAL - SAVANT	Moderate to severe spasticity due to MS (multiple sclerosis). MedDRA version: 19.0;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SATIVEX INN or Proposed INN: Cannabidiol Botanical Drug Substance (CBD BDS) Other descriptive name: CANNABIDIOL INN or Proposed INN: TETRAHYDROCANNABINOL Botanical Drug Substance (THC BDS) Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL	Almirall Hermal GmbH	NULL	Not Recruiting			Female: yes Male: yes	228	Phase 4	Czech Republic;Austria
13	EUCTR2011-000985-36-ES (EUCTR)	22/02/2013	25/01/2012	Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex	Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex	Spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex MedDRA version: 14.1;Level: LLT;Classification code 10041416;Term: Spasticity;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: SATIVEX Product Name: sativex Product Code: N02BG10 INN or Proposed INN: pending Other descriptive name: CANNABIDIOL	JOSE MANUEL GARCIA DOMINGUEZ	NULL	Not Recruiting			Female: yes Male: yes			Spain
14	EUCTR2011-002258-30-IT (EUCTR)	04/10/2011	10/04/2012	CLINICAL STUDY TO EVALUATE THE EFFECTIVENESS OF Sativex in relieving pain PEOPLE AFFECTED BY MULTIPLE SCLEROSIS	NEUROPHYSIOLOGIC STUDY AIMED AT EVALUATING ON EFFECT OF SATIVEX® ON SPASTICITY IN PROGRESSIVE MULTIPLE SCLEROSIS - M/SATIVX/01	Subject of both male and female gender affected by Secondary-Progressive (SP) or Primary-Progressive (PP) MS MedDRA version: 14.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SATIVEX INN or Proposed INN: CANNABIDIOL INN or Proposed INN: DELTA-9-TETRAHYDROCANNABINOL	ALMIRALL PRODESFARMA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
15	EUCTR2011-000926-31-CZ (EUCTR)	29/06/2011	25/05/2011	A long term, 50 week, Phase IV multi-centre study to determine if Sativex has an effect on cognition (thinking ability) when prescribed to patients with spasticity due to MS	A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex onCognitive Function and Mood of Patients with Spasticity due toMultiple Sclerosis	Spasticity in multiple sclerosis (MS). MedDRA version: 14.1;Level: LLT;Classification code 10041416;Term: Spasticity;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sativex Oromucosal Spray INN or Proposed INN: N/A Other descriptive name: delta-9-tetrahydrocannabinol INN or Proposed INN: N/A Other descriptive name: cannabidiol	GW Pharma Ltd.	NULL	Not Recruiting			Female: yes Male: yes	120	Phase 4	Czech Republic
16	EUCTR2006-005910-11-DE (EUCTR)	08/05/2008	08/02/2008	A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study.	A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study.	Spasticity in multiple sclerosis (MS)	Trade Name: Sativex Product Name: Sativex Product Code: GW-1000-02 Other descriptive name: delta-9-tetrahydrocannabinol Other descriptive name: Cannabidiol	GW Pharma Ltd.	NULL	Not Recruiting			Female: yes Male: yes	488	Phase 3	United Kingdom;Germany;Spain;Italy
17	EUCTR2006-005910-11-GB (EUCTR)	09/01/2008	14/08/2007	A two-phase, Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study.	A two-phase, Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study.	Spasticity in multiple sclerosis (MS)	Trade Name: Sativex Product Name: Sativex Product Code: GW-1000-02 Other descriptive name: delta-9-tetrahydrocannabinol Other descriptive name: Cannabidiol	GW Pharma Ltd.	NULL	Not Recruiting			Female: yes Male: yes	575	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Czech Republic;Spain;Germany;Italy;United Kingdom
18	EUCTR2007-002138-13-GB (EUCTR)	13/09/2007	14/06/2007	A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®).	A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®).	Symptoms of spasticity in multiple sclerosis.	Trade Name: Sativex Product Name: Sativex Product Code: GW-1000-02 Other descriptive name: delta-9-tetrahydrocannabinol Other descriptive name: Cannabidiol	GW Pharma Ltd.	NULL	Not Recruiting			Female: yes Male: yes			United Kingdom
19	EUCTR2006-005910-11-CZ (EUCTR)	29/08/2007	10/07/2007	A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study.	A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study.	Spacticity in multiple sclerosis (MS)	Product Name: Sativex Product Code: GW-1000-02 Other descriptive name: delta-9-tetrahydrocannabinol Other descriptive name: Cannabidiol	GW Pharma Ltd	NULL	Not Recruiting			Female: yes Male: yes	488	Phase 3	Czech Republic;Spain;Germany;Italy;United Kingdom
20	EUCTR2005-005265-11-FR (EUCTR)	14/12/2006	27/10/2006	A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis.	A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis.	Relief of central neuropathic pain in subjects with multiple sclerosis (MS)	Product Name: Sativex Product Code: GW-1000-02 Other descriptive name: delta-9-tetrahydrocannabinol Other descriptive name: Cannabidiol	GW Pharma Ltd	NULL	Not Recruiting			Female: yes Male: yes	218	Phase 3	France;Czech Republic;United Kingdom
21	EUCTR2005-005265-11-CZ (EUCTR)	17/10/2006	24/08/2006	A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis.This will be followed by a 12 week open label treatment phase and then a 4 week randomised withdrawal phase (Part B) for a subset of subjects.	A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis.This will be followed by a 12 week open label treatment phase and then a 4 week randomised withdrawal phase (Part B) for a subset of subjects.	Relief of central neuropathic pain in subjects with multiple sclerosis (MS)	Product Name: Sativex Product Code: GW-1000-02 Other descriptive name: delta-9-tetrahydrocannabinol Other descriptive name: Cannabidiol	GW Pharma Ltd	NULL	Not Recruiting			Female: yes Male: yes	312		United Kingdom;Czech Republic;France
22	EUCTR2005-005265-11-GB (EUCTR)	03/04/2006	24/02/2006	A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis. This will be followed by a 12 week open label treatment phase and then a 4 week randomised withdrawal phase (Part B) for a subset of subjects	A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis. This will be followed by a 12 week open label treatment phase and then a 4 week randomised withdrawal phase (Part B) for a subset of subjects	Relief of central neuropathic pain in subjects with multiple sclerosis (MS)	Product Name: Sativex Product Code: GW-1000-02 Other descriptive name: delta-9-tetrahydrocannabinol Other descriptive name: Cannabidiol	GW Pharma Ltd	NULL	Not Recruiting			Female: yes Male: yes	312	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France;Czech Republic;United Kingdom
23	EUCTR2004-002509-63-CZ (EUCTR)	11/03/2005	04/02/2005	A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis - N/A	A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis - N/A	Spasticity due to Multiple Sclerosis (MS)	Product Name: Sativex Product Code: GW-1000-02 Other descriptive name: delta-9-tetrahydrocannabinol Other descriptive name: cannabidiol	GW Pharma Ltd	NULL	Not Recruiting			Female: yes Male: yes	284		United Kingdom;Czech Republic
24	EUCTR2004-002509-63-GB (EUCTR)	21/02/2005	23/02/2005	A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis - N/A	A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis - N/A	Spasticity due to Multiple Sclerosis (MS)	Product Name: Sativex Product Code: GW-1000-02 Other descriptive name: delta-9-tetrahydrocannabinol Other descriptive name: cannabidiol	GW Pharma Ltd	NULL	Not Recruiting			Female: yes Male: yes	284	Phase 3	Czech Republic;United Kingdom
25	NCT01610687 (ClinicalTrials.gov)	July 2001	31/5/2012	A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis	A Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension	Multiple Sclerosis;Spasticity	Drug: GW-1000-02	GW Pharmaceuticals Ltd.	NULL	Completed	18 Years	N/A	All	137	Phase 3	United Kingdom
26	NCT01610713 (ClinicalTrials.gov)	May 2001	31/5/2012	An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis	Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension	Multiple Sclerosis	Drug: GW-1000-02	GW Pharmaceuticals Ltd.	NULL	Completed	18 Years	N/A	All	154	Phase 3	United Kingdom
27	NCT01610700 (ClinicalTrials.gov)	May 2001	31/5/2012	An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients	Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension	Multiple Sclerosis	Drug: GW-1000-02;Drug: Placebo	GW Pharmaceuticals Ltd.	NULL	Completed	18 Years	N/A	All	160	Phase 3	United Kingdom

先頭へ

36. 表皮水疱症

臨床試験数 : 160 / 薬物数 : 195 - (DrugBank : 47) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04613102 (ClinicalTrials.gov)	August 1, 2020	27/10/2020	The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial	The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial	Epidermolysis Bullosa;Pain;Itch	Drug: AVCN583601 (3% Cannabidiol cream)	Elena Pope	Avicanna Inc	Withdrawn	4 Years	50 Years	All	0	Phase 2/Phase 3	Canada
2	EUCTR2021-000103-20-NL (EUCTR)		15/07/2021	A study on the effect of Transvamix on pain in adults with epidermolysis bullosa.	An explorative randomized, placebo-controlled and double-blind intervention crossover study: Transvamix (100mg/mL THC / 50mg/mL CBD) to treat chronic pain in Epidermolysis Bullosa	Genetic Epidermolysis Bullosa;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]	Product Name: Transvamix (100mg/mL THC, 50mg/mL CBD) INN or Proposed INN: THC Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: CBD Other descriptive name: CANNABIDIOL	University Medical Center Groningen	NULL	NA			Female: yes Male: yes	16	Phase 2	Netherlands

46. 悪性関節リウマチ

臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04911127 (ClinicalTrials.gov)	October 5, 2021	14/5/2021	Therapeutic Response of Cannabidiol in Rheumatoid Arthritis	Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Cannabidiol (CBD) in Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis;Cannabis	Drug: 200mg Cannabidiol by capsules twice daily;Drug: 400mg Cannabidiol by capsules twice daily;Drug: Placebo capsules	University of California, Los Angeles	NULL	Recruiting	18 Years	N/A	All	60	Phase 1/Phase 2	United States
2	EUCTR2017-004226-15-DK (EUCTR)	26/10/2018	05/01/2018	Can-Art Effect and safety of using Canabis derivatives for the treatment of pain in patients with inflammatory Arthritis, such as reumatoid arthritis and ankylosing spondylitis, the latter being a type of arthritis that causes a long term inflammation of the joints of the spine. A randomized, double blinded, placebo controlled trial, i.e. in this drug trial, a control group is given a placebo while another group is given the Cannabis derivative being studied.	CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A randomized, double blinded, placebo controlled trial - Can-Art	Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) MedDRA version: 20.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Cannabidiol tablet 10 mg Other descriptive name: CANNABIDIOL Product Name: Dronabinol capsule 2.5. mg INN or Proposed INN: DRONABINOL	King Christian 10th Hospital for Rheumatology	NULL	Not Recruiting			Female: yes Male: yes	180	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Denmark

95. 自己免疫性肝炎

臨床試験数 : 52 / 薬物数 : 68 - (DrugBank : 28) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 112

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04129489 (ClinicalTrials.gov)	February 7, 2019	18/3/2019	A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis	A Phase 2a Open Label, Single Arm Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis	Autoimmune Hepatitis	Drug: Cannabidiol	Stero Biotechs Ltd.	NULL	Terminated	18 Years	N/A	All	2	Phase 2	Israel

96. クローン病

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04056442 (ClinicalTrials.gov)	July 7, 2019	13/8/2019	A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients	Steroid Dependent Crohn's Disease	Drug: Cannabidiol , synthetic form;Drug: Placebo	Stero Biotechs Ltd.	NULL	Recruiting	18 Years	N/A	All	28	Phase 2	Israel
2	NCT03467620 (ClinicalTrials.gov)	July 2018	5/3/2018	Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease	Oral Cannabidiol Capsule Usage as an Adjunct Therapy for Crohn's Disease: a Randomized, Placebo-controlled Study	Crohn Disease;Inflammatory Bowel Diseases;Cannabis	Drug: Cannabidiol;Drug: Placebo oral capsule	University of Illinois at Chicago	NULL	Withdrawn	18 Years	N/A	All	0	Phase 2/Phase 3	NULL
3	NCT01037322 (ClinicalTrials.gov)	January 2010	20/12/2009	Cannabidiol for Inflammatory Bowel Disease	Use of Cannabidiol for the Treatment of Inflammatory Bowel Disease	Crohn's Disease;Ulcerative Colitis	Drug: cannabidiol;Drug: placebo in drops	Meir Medical Center	NULL	Completed	20 Years	80 Years	Both	20	Phase 1/Phase 2	Israel

97. 潰瘍性大腸炎

臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-003208-19-CZ (EUCTR)	05/09/2013	03/04/2013	GWP42003 symptomatic treatment of ulcerative colitis.	A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the symptomatic treatment of ulcerative colitis.	Symptoms of diarrhoea, rectal bleeding, stool frequency and inflammation in subjects with ulcerative colitis MedDRA version: 16.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: GWP42003 INN or Proposed INN: Not Applicable Other descriptive name: CANNABIDIOL	GW Pharma Ltd.	NULL	Not Recruiting			Female: yes Male: yes	62	Phase 2	Czech Republic;United Kingdom
2	EUCTR2011-003208-19-GB (EUCTR)	16/11/2011	28/09/2011	GWP42003 symptomatic treatment of ulcerative colitis.	A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the symptomatic treatment of ulcerative colitis.	Symptoms of diarrhoea, rectal bleeding, stool frequency and inflammation in subjects with ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: GWP42003 INN or Proposed INN: Not applicable Other descriptive name: CANNABIDIOL	GW Pharma Ltd.	NULL	Not Recruiting			Female: yes Male: yes	62	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Czech Republic;United Kingdom
3	NCT01037322 (ClinicalTrials.gov)	January 2010	20/12/2009	Cannabidiol for Inflammatory Bowel Disease	Use of Cannabidiol for the Treatment of Inflammatory Bowel Disease	Crohn's Disease;Ulcerative Colitis	Drug: cannabidiol;Drug: placebo in drops	Meir Medical Center	NULL	Completed	20 Years	80 Years	Both	20	Phase 1/Phase 2	Israel

140. ドラベ症候群

臨床試験数 : 104 / 薬物数 : 61 - (DrugBank : 14) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05044819 (ClinicalTrials.gov)	July 7, 2021	30/8/2021	Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution	A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution	Lennox Gastaut Syndrome;Dravet Syndrome;Tuberous Sclerosis Complex	Drug: Cannabidiol	GW Research Ltd	NULL	Recruiting	1 Year	N/A	All	150	Phase 4	United States
2	NCT04611438 (ClinicalTrials.gov)	March 30, 2020	16/9/2019	Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome	A Prospective Multi-Center Single-Arm Clinical Trial on Cognitive Effect of Cannabidiol (CBD-OS®) on Dravet Syndrome and Lennox-Gastaut Syndrome	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: Cannabidiol	Yonsei University	NULL	Recruiting	2 Years	18 Years	All	107	Phase 3	Korea, Republic of
3	NCT03467113 (ClinicalTrials.gov)	January 19, 2018	30/1/2018	A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol	An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: ZX008 0.2 to 0.8 mg/kg/day;Drug: Cannabidiol	Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.	NULL	Completed	2 Years	18 Years	All	9	Phase 1/Phase 2	United States
4	NCT02318563 (ClinicalTrials.gov)	December 30, 2017	12/12/2014	Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome	A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome	Dravet Syndrome	Drug: Cannabidiol Oral Solution;Drug: Placebo Solution	INSYS Therapeutics Inc	NULL	Withdrawn	1 Year	30 Years	All	0	Phase 3	NULL
5	NCT02815540 (ClinicalTrials.gov)	February 16, 2017	20/6/2016	The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy	The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children	Lennox-Gastaut Syndrome;Dravet Syndrome	Procedure: 12-Lead ECG;Drug: Cannabidiol	Gillette Children's Specialty Healthcare	NULL	Terminated	2 Years	30 Years	All	2	Phase 1/Phase 2	United States
6	EUCTR2014-001834-27-NL (EUCTR)	09/09/2015	18/06/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut Syndromes	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 3	United States;France;Spain;Poland;Australia;Israel;Netherlands;United Kingdom
7	EUCTR2014-001834-27-FR (EUCTR)	03/09/2015	20/07/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut Syndromes	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 18.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	530	Phase 3	United States;France;Spain;Poland;Israel;Netherlands;United Kingdom
8	EUCTR2014-001834-27-PL (EUCTR)	18/08/2015	14/05/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut Syndromes	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 3	United States;France;Spain;Poland;Australia;Israel;Netherlands;United Kingdom
9	NCT02224573 (ClinicalTrials.gov)	June 2015	21/8/2014	GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes	An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Young Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes.	Epilepsy;Dravet Syndrome;Lennox-Gastaut Syndrome	Drug: GWP42003-P	GW Research Ltd	NULL	Completed	2 Years	N/A	All	681	Phase 3	NULL
10	EUCTR2014-001834-27-ES (EUCTR)	21/05/2015	14/04/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut Syndromes	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 18.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	430	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France;United States;Poland;Spain;Israel;Netherlands;United Kingdom
11	NCT02224703 (ClinicalTrials.gov)	April 13, 2015	21/8/2014	GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome	A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome.	Epilepsy;Dravet Syndrome	Drug: GWP42003-P;Drug: Placebo Control	GW Research Ltd	NULL	Completed	2 Years	18 Years	All	199	Phase 3	United States;Australia;Israel;Netherlands;Poland;Spain
12	EUCTR2014-002939-34-ES (EUCTR)	08/04/2015	16/12/2014	A study of the safety and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.	Dravet syndrome MedDRA version: 17.1;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	120	Phase 3	United States;Poland;Spain;Israel;Netherlands;United Kingdom
13	NCT02091375 (ClinicalTrials.gov)	March 30, 2015	17/3/2014	Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)	A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome	Epilepsy;Dravet Syndrome	Drug: GWP42003-P 20 mg/kg/day Dose;Drug: Placebo control	GW Research Ltd	NULL	Completed	2 Years	18 Years	All	120	Phase 3	United States;France;Poland;United Kingdom
14	EUCTR2014-000995-24-PL (EUCTR)	09/03/2015	31/10/2014	A study of the safety, pharmacokinetics and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome	A double-blind, placebo-controlled two-part study to investigate the dose-ranging safety and pharmacokinetics, followed by the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.	Dravet Syndrome MedDRA version: 18.1;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	125		France;United States;Poland;United Kingdom
15	EUCTR2014-002939-34-NL (EUCTR)	04/03/2015	16/03/2015	A study of the safety and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.	Dravet syndrome MedDRA version: 20.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	186	Phase 3	United States;Poland;Spain;Australia;Israel;Netherlands;United Kingdom
16	EUCTR2014-001834-27-GB (EUCTR)	14/01/2015	30/09/2014	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut Syndromes	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	680	Phase 3	France;United States;Poland;Spain;Australia;Israel;Netherlands;United Kingdom
17	EUCTR2014-002939-34-GB (EUCTR)	29/12/2014	24/09/2014	A study of the safety and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.	Dravet syndrome MedDRA version: 17.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	120	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Poland;Spain;Israel;Netherlands;United Kingdom
18	NCT02091206 (ClinicalTrials.gov)	October 22, 2014	17/3/2014	A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)	A Double Blind, Placebo-controlled, Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome	Epilepsy;Dravet Syndrome	Drug: GWP42003-P 5 mg/kg/day Dose;Drug: Placebo control;Drug: GWP42003-P 10 mg/kg/day Dose;Drug: GWP42003-P 20 mg/kg/day Dose	GW Research Ltd	NULL	Completed	4 Years	10 Years	All	34	Phase 2	United States;United Kingdom
19	EUCTR2014-000995-24-GB (EUCTR)	09/09/2014	04/07/2014	A study of the safety, pharmacokinetics and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome	A double-blind, placebo-controlled two-part study to investigate the dose-ranging safety and pharmacokinetics, followed by the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.	Dravet Syndrome MedDRA version: 18.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	125	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France;United States;Poland;United Kingdom
20	EUCTR2014-002939-34-PL (EUCTR)		25/01/2016	A study of the safety and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.	Dravet syndrome MedDRA version: 20.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	186	Phase 3	United States;Spain;Poland;Australia;Israel;Netherlands;United Kingdom

先頭へ

144. レノックス・ガストー症候群

臨床試験数 : 101 / 薬物数 : 68 - (DrugBank : 12) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 60

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05044819 (ClinicalTrials.gov)	July 7, 2021	30/8/2021	Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution	A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution	Lennox Gastaut Syndrome;Dravet Syndrome;Tuberous Sclerosis Complex	Drug: Cannabidiol	GW Research Ltd	NULL	Recruiting	1 Year	N/A	All	150	Phase 4	United States
2	NCT04133480 (ClinicalTrials.gov)	October 2020	17/10/2019	Investigation of Cognitive Outcomes With Cannabidiol Oral Solution	An Open-Label Exploratory Investigation of Cognitive Outcomes With Cannabidiol Oral Solution (EPIDIOLEX®; GWP42003-P)	Lennox-Gastaut Syndrome	Drug: GWP42003-P	GW Research Ltd	NULL	Withdrawn	3 Years	10 Years	All	0	Phase 4	United States
3	NCT04611438 (ClinicalTrials.gov)	March 30, 2020	16/9/2019	Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome	A Prospective Multi-Center Single-Arm Clinical Trial on Cognitive Effect of Cannabidiol (CBD-OS®) on Dravet Syndrome and Lennox-Gastaut Syndrome	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: Cannabidiol	Yonsei University	NULL	Recruiting	2 Years	18 Years	All	107	Phase 3	Korea, Republic of
4	NCT03467113 (ClinicalTrials.gov)	January 19, 2018	30/1/2018	A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol	An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: ZX008 0.2 to 0.8 mg/kg/day;Drug: Cannabidiol	Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.	NULL	Completed	2 Years	18 Years	All	9	Phase 1/Phase 2	United States
5	NCT02318537 (ClinicalTrials.gov)	December 30, 2017	12/12/2014	Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome	A Multicenter, Randomized, Double-blind, Placebo-controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome	Lennox-Gastaut Syndrome	Drug: Cannabidiol Oral Solution;Drug: Placebo Solution	INSYS Therapeutics Inc	NULL	Withdrawn	2 Years	30 Years	All	0	Phase 3	NULL
6	NCT02815540 (ClinicalTrials.gov)	February 16, 2017	20/6/2016	The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy	The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children	Lennox-Gastaut Syndrome;Dravet Syndrome	Procedure: 12-Lead ECG;Drug: Cannabidiol	Gillette Children's Specialty Healthcare	NULL	Terminated	2 Years	30 Years	All	2	Phase 1/Phase 2	United States
7	EUCTR2014-002941-23-NL (EUCTR)	30/09/2015	31/03/2015	Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures associated with Lennox-Gastaut Syndrome in children and adults	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syndrome in children and adults	Lennox-Gastaut syndrome MedDRA version: 19.0;Level: PT;Classification code 10048816;Term: Lennox-Gastaut syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd.	NULL	Not Recruiting			Female: yes Male: yes	100		United States;Poland;Netherlands
8	EUCTR2014-001834-27-NL (EUCTR)	09/09/2015	18/06/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut Syndromes	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 3	United States;France;Spain;Poland;Australia;Israel;Netherlands;United Kingdom
9	EUCTR2014-001834-27-FR (EUCTR)	03/09/2015	20/07/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut Syndromes	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 18.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	530	Phase 3	United States;France;Spain;Poland;Israel;Netherlands;United Kingdom
10	EUCTR2014-001834-27-PL (EUCTR)	18/08/2015	14/05/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut Syndromes	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 3	United States;France;Spain;Poland;Australia;Israel;Netherlands;United Kingdom
11	EUCTR2014-002940-42-GB (EUCTR)	28/07/2015	26/09/2014	A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in children and adults.	Lennox-Gastaut syndrome (LGS) MedDRA version: 18.0;Level: PT;Classification code 10048816;Term: Lennox-Gastaut syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	150	Phase 3	France;United States;Spain;United Kingdom
12	EUCTR2014-002941-23-PL (EUCTR)	16/07/2015	01/04/2015	Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures associated with Lennox-Gastaut Syndrome in children and adults	A randomized, double-blind, placebo-controlled study toinvestigate the efficacy and safety of cannabidiol (GWP42003-P;CBD) as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in children and adults	Lennox-Gastaut syndrome MedDRA version: 18.1;Level: PT;Classification code 10048816;Term: Lennox-Gastaut syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd.	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 3	United States;Poland;Netherlands
13	NCT02224560 (ClinicalTrials.gov)	June 8, 2015	21/8/2014	Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults	A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.	Epilepsy;Lennox Gastaut Syndrome	Drug: GWP42003-P;Drug: Placebo control	GW Research Ltd	NULL	Completed	2 Years	55 Years	All	225	Phase 3	United States;France;Spain;United Kingdom
14	NCT02224573 (ClinicalTrials.gov)	June 2015	21/8/2014	GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes	An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Young Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes.	Epilepsy;Dravet Syndrome;Lennox-Gastaut Syndrome	Drug: GWP42003-P	GW Research Ltd	NULL	Completed	2 Years	N/A	All	681	Phase 3	NULL
15	EUCTR2014-001834-27-ES (EUCTR)	21/05/2015	14/04/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut Syndromes	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 18.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	430	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France;United States;Poland;Spain;Israel;Netherlands;United Kingdom
16	NCT02224690 (ClinicalTrials.gov)	April 28, 2015	21/8/2014	A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults	A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.	Epilepsy;Lennox-Gastaut Syndrome	Drug: GWP42003-P 20 mg/kg/day Dose;Drug: Placebo	GW Research Ltd	NULL	Completed	2 Years	55 Years	All	171	Phase 3	United States;Netherlands;Poland
17	EUCTR2014-002940-42-ES (EUCTR)	08/04/2015	16/12/2014	A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in children and adults.	Lennox-Gastaut syndrome (LGS) MedDRA version: 17.1;Level: PT;Classification code 10048816;Term: Lennox-Gastaut syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	120	Phase 3	France;United States;Spain;United Kingdom
18	EUCTR2014-001834-27-GB (EUCTR)	14/01/2015	30/09/2014	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut Syndromes	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification code 10073677;Term: Severe myoclonic epilepsy of infancy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	680	Phase 3	France;United States;Poland;Spain;Australia;Israel;Netherlands;United Kingdom

先頭へ

145. ウエスト症候群

臨床試験数 : 43 / 薬物数 : 54 - (DrugBank : 15) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 24

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03421496 (ClinicalTrials.gov)	September 5, 2018	26/1/2018	A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile Spasms	Infantile Spasm	Drug: Cannabidiol Oral Solution;Drug: Placebo;Drug: Vigabatrin	Benuvia Therapeutics Inc.	NULL	Terminated	1 Month	24 Months	All	2	Phase 3	United States
2	NCT02954887 (ClinicalTrials.gov)	May 12, 2017	2/11/2016	Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)	A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study	Infantile Spasms	Drug: GWP42003-P	GW Research Ltd	NULL	Completed	1 Month	24 Months	All	9	Phase 3	United States;Poland
3	NCT02953548 (ClinicalTrials.gov)	April 24, 2017	1/11/2016	Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)	A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study	Infantile Spasms	Drug: GWP42003-P	GW Research Ltd	NULL	Completed	1 Month	24 Months	All	9	Phase 3	United States;Poland
4	EUCTR2015-004904-50-PL (EUCTR)		04/04/2017	Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms	A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of Cannabidiol (GWP42003-P) in infants with Infantile Spasms following an initial open label pilot study.	Infantile Spasms MedDRA version: 20.1;Level: PT;Classification code 10021750;Term: Infantile spasms;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: Cannabidiol Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	202	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Hungary;Poland;Italy;United Kingdom

156. レット症候群

臨床試験数 : 40 / 薬物数 : 53 - (DrugBank : 19) / 標的遺伝子数 : 77 - 標的パスウェイ数 : 113

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001605-24-IT (EUCTR)	02/11/2020	21/01/2021	An open label extension study for long-term safety of GWP42003-P in patients with Rett Syndrome	An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome - NA	Rett syndrome (RTT) [typical or atypical] MedDRA version: 20.0;Level: PT;Classification code 10077709;Term: Rett syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: CBD soluzione orale nota come Epidyolex e con tale nome è stato approvato in UE Product Name: Cannabidiolo Product Code: [GWP42003-P] INN or Proposed INN: cannabidiolo Other descriptive name: cannabidiol	GW RESEARCH LTD.	NULL	NA			Female: yes Male: no	252	Phase 3	United States;Canada;Spain;Australia;United Kingdom;Italy
2	EUCTR2019-001605-24-ES (EUCTR)	04/03/2020	21/02/2020	An open label extension study for long-term safety of GWP42003-P in patients with Rett Syndrome	An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome	Rett syndrome (RTT) [typical or atypical] MedDRA version: 20.0;Level: PT;Classification code 10077709;Term: Rett syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Epidyolex and is the approved name in the EU Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: Cannabidiol Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: no	252	Phase 3	United States;Canada;Spain;Australia;United Kingdom;Italy
3	NCT04252586 (ClinicalTrials.gov)	February 28, 2020	30/1/2020	An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome	An Open-label Extension Trial to Investigate the Long-term Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome	Rett Syndrome;RTT	Drug: GWP42003-P	GW Research Ltd	NULL	Terminated	2 Years	18 Years	All	21	Phase 3	United States;Australia;Canada;Italy;Spain;United Kingdom
4	EUCTR2019-001605-24-GB (EUCTR)	15/01/2020	23/10/2019	An open label extension study for long-term safety of GWP42003-P in patients with Rett Syndrome	An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome	Rett syndrome (RTT) [typical or atypical] MedDRA version: 20.0;Level: PT;Classification code 10077709;Term: Rett syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: CBD Oral solution, is known as Epidyolex and is the approved name in the EU Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: Cannabidiol Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	252	Phase 3	United States;France;Canada;Spain;Australia;Italy;United Kingdom
5	EUCTR2018-003370-27-IT (EUCTR)	18/09/2019	24/05/2021	A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome.	A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome. - Not applicable	Rett syndrome (RTT) [typical or atypical] MedDRA version: 20.0;Level: PT;Classification code 10077709;Term: Rett syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: CBD - Solution Orale, conosciuto come Epidiolex, questo è il nome approvato negli Stati Uniti Product Name: Cannabidiolo (CBD) Product Code: [GWP42003-P] INN or Proposed INN: Cannabidiolo Other descriptive name: Cannabidiol	GW RESEARCH LTD.	NULL	Not Recruiting			Female: yes Male: no	252	Phase 3	United States;Canada;Spain;Germany;United Kingdom;Italy
6	NCT03848832 (ClinicalTrials.gov)	July 29, 2019	19/2/2019	Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome	A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome	Rett Syndrome;RTT	Drug: GWP42003-P;Drug: Placebo	GW Research Ltd	NULL	Terminated	2 Years	18 Years	Female	252	Phase 3	United States;Italy;Spain;United Kingdom
7	EUCTR2018-003370-27-GB (EUCTR)	09/04/2019	24/12/2018	A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome.	A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome.	Rett syndrome (RTT) [typical or atypical] MedDRA version: 20.0;Level: PT;Classification code 10077709;Term: Rett syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: CBD - Oral Solution, is known as Epidyolex, and is the approved name Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: Cannabidiol Other descriptive name: CANNABIDIOL	GW Research Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	252	Phase 2;Phase 3	United States;France;Canada;Spain;Australia;Italy;United Kingdom

先頭へ

157. スタージ・ウェーバー症候群

臨床試験数 : 10 / 薬物数 : 14 - (DrugBank : 4) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04447846 (ClinicalTrials.gov)	October 14, 2019	10/10/2019	Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome	Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: A Phase II Trial	Sturge-Weber Syndrome	Drug: Cannabidiol	Anne Comi, MD	Jazz Pharmaceuticals;Faneca 66 Foundation	Completed	3 Years	50 Years	All	10	Phase 2	United States
2	NCT02332655 (ClinicalTrials.gov)	December 2014	5/1/2015	Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome	Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome	Sturge-Weber Syndrome	Drug: Cannabidiol	Anne Comi, MD	GW Pharmaceuticals Ltd.;Faneca 66 Foundation	Active, not recruiting	1 Month	45 Years	All	5	Phase 1/Phase 2	United States

158. 結節性硬化症

臨床試験数 : 108 / 薬物数 : 67 - (DrugBank : 17) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05044819 (ClinicalTrials.gov)	July 7, 2021	30/8/2021	Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution	A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution	Lennox Gastaut Syndrome;Dravet Syndrome;Tuberous Sclerosis Complex	Drug: Cannabidiol	GW Research Ltd	NULL	Recruiting	1 Year	N/A	All	150	Phase 4	United States
2	NCT04485104 (ClinicalTrials.gov)	May 19, 2021	21/7/2020	Safety, Pharmacokinetics, and Exploratory Efficacy Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared With Standard of Care Antiseizure Medication, in Participants Age 1 Month to <12 Months of Age With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures	An Open-label, Randomized Trial to Assess the Safety, Pharmacokinetics, and Exploratory Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared With Standard of Care Antiseizure Medication, in Patients Age 1 Month to Less Than 12 Months of Age With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures	Seizure in Participants With Tuberous Sclerosis Complex	Drug: GWP42003-P;Drug: SOC	GW Research Ltd	NULL	Recruiting	1 Month	11 Months	All	12	Phase 3	United States
3	EUCTR2015-002154-12-NL (EUCTR)	01/09/2017	17/01/2017	A study of cannabidiol (GWP42003-P, CBD) in patients with tuberous sclerosis complex who experience seizures.	A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled seizures	Tuberous Sclerosis Complex (TSC) MedDRA version: 20.0;Level: PT;Classification code 10045138;Term: Tuberous sclerosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: CBD-Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd.	NULL	Not Recruiting			Female: yes Male: yes	210	Phase 3	United States;Spain;Poland;Australia;Netherlands;United Kingdom
4	EUCTR2015-002154-12-ES (EUCTR)	30/09/2016	15/07/2016	A study of cannabidiol (GWP42003-P, CBD) in patients with tuberous sclerosis complex who experience seizures.	A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled seizures	Tuberous Sclerosis Complex (TSC) MedDRA version: 19.0;Level: PT;Classification code 10045138;Term: Tuberous sclerosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd.	NULL	Not Recruiting			Female: yes Male: yes	192	Phase 3	United States;France;Poland;Spain;Australia;Netherlands;United Kingdom
5	NCT02544750 (ClinicalTrials.gov)	August 2016	7/9/2015	An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)	A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures	Tuberous Sclerosis Complex;Seizures	Drug: GWP42003-P	GW Research Ltd	NULL	Completed	1 Year	65 Years	All	224	Phase 3	United States
6	NCT02544763 (ClinicalTrials.gov)	April 6, 2016	7/9/2015	A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)	A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures	Tuberous Sclerosis Complex;Seizures	Drug: GWP42003-P;Drug: Placebo	GW Research Ltd	NULL	Completed	1 Year	65 Years	All	224	Phase 3	United States;Australia;Netherlands;Poland;Spain;United Kingdom
7	EUCTR2015-002154-12-PL (EUCTR)		18/11/2016	A study of cannabidiol (GWP42003-P, CBD) in patients with tuberous sclerosis complex who experience seizures.	A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled seizures	Tuberous Sclerosis Complex (TSC) MedDRA version: 21.0;Level: LLT;Classification code 10045138;Term: Tuberous sclerosis;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: CBD - Oral Solution, is known as Epidyolex 100 mg/ml oral solution, Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name: CANNABIDIOL	GW Research Ltd.	NULL	Not Recruiting			Female: yes Male: yes	210	Phase 3	United States;Spain;Poland;Australia;Netherlands;United Kingdom
8	EUCTR2020-002132-67-Outside-EU/EEA (EUCTR)		22/10/2021	Safety, Pharmacokinetics, and Exploratory Efficacy Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared With Standard of Care Antiseizure Medication, in Patients Age 1 Month to <12 Months of Age With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures	An Open-Label, Randomized Trial to Assess the Safety, Pharmacokinetics, and Exploratory Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared with Standard of Care Antiseizure Medication, in Patients Age 1 Month to Less than 12 Months of Age with Tuberous Sclerosis Complex who Experience Inadequately-Controlled SeizuresP/0047/2020P/0350/2020P/0033/2021	Tuberous Sclerosis Complex (TSC) MedDRA version: 21.0;Level: LLT;Classification code 10045138;Term: Tuberous sclerosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 21.0;Level: PT;Classification code 10080584;Term: Tuberous sclerosis complex;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Cannabidiol Oral Solution, is known as Epidyolex 100 mg/mL oral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US. Product Name: Cannabidiol (CBD) Product Code: GWP42003-P	GW Research Ltd	NULL	NA			Female: yes Male: yes		Phase 3	United States

先頭へ

193. プラダー・ウィリ症候群

臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05098509 (ClinicalTrials.gov)	March 15, 2022	22/9/2021	A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Willi Syndrome	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome	Prader-Willi Syndrome	Drug: RAD011;Drug: Placebo	Radius Pharmaceuticals, Inc.	NULL	Not yet recruiting	8 Years	65 Years	All	220	Phase 2/Phase 3	United States
2	NCT03458416 (ClinicalTrials.gov)	September 6, 2018	2/3/2018	A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome	A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome	Prader-Willi Syndrome	Drug: Cannabidiol Oral Solution	Benuvia Therapeutics Inc.	NULL	Terminated	8 Years	17 Years	All	7	Phase 2	United States
3	NCT02844933 (ClinicalTrials.gov)	June 6, 2018	22/7/2016	Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome	Prader-Willi Syndrome	Drug: Cannabidiol;Drug: Placebo	Benuvia Therapeutics Inc.	NULL	Terminated	8 Years	17 Years	All	7	Phase 2	United States

206. 脆弱Ｘ症候群

臨床試験数 : 104 / 薬物数 : 87 - (DrugBank : 32) / 標的遺伝子数 : 54 - 標的パスウェイ数 : 79

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04977986 (ClinicalTrials.gov)	September 13, 2021	20/7/2021	Clinical Study of Cannabidiol in Children and Adolescents With Fragile X Syndrome	A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome - RECONNECT	Fragile X Syndrome	Drug: ZYN002 - transdermal gel;Drug: Placebo	Zynerba Pharmaceuticals, Inc.	NULL	Recruiting	3 Years	17 Years	All	204	Phase 3	United States;Australia;Ireland;United Kingdom
2	NCT03614663 (ClinicalTrials.gov)	June 12, 2018	10/7/2018	Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)	A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome	Fragile X Syndrome	Drug: ZYN002 - CBD Transdermal Gel;Other: Placebo Transdermal Gel	Zynerba Pharmaceuticals, Inc.	NULL	Completed	3 Years	17 Years	All	212	Phase 2/Phase 3	United States;Australia;New Zealand
3	EUCTR2021-002542-33-IE (EUCTR)		10/08/2021	Effects and Safety of Test drug ZYN002, applied as a gel onto the skin of children and adolescents with a certain hereditary disease called Fragile X Syndrome	A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome - RECONNECT - RECONNECT	Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X mental retardation protein (FMRP), an RNA-binding protein and the gene product of the FMR1 gene. FXS is most commonly caused by silencing of the FMR1 gene due to a trinucleotide repeat expansion. In FXS patients, the relative absence of functional FMRP is associated with critical impairments in neurodevelopment and learning, as well as disruption to other neuronal and non-neuronal functions. MedDRA version: 20.1;Level: PT;Classification code 10017324;Term: Fragile X syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Code: ZYN002 INN or Proposed INN: n/a Other descriptive name: CANNABIDIOL	Zynerba Pharmaceuticals, Inc.	NULL	NA			Female: yes Male: yes	204	Phase 3	United States;Ireland;Australia;United Kingdom

226. 間質性膀胱炎（ハンナ型）

臨床試験数 : 143 / 薬物数 : 171 - (DrugBank : 56) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04349930 (ClinicalTrials.gov)	January 2021	13/4/2020	The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC)	The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC)	Interstitial Cystitis;Bladder Pain Syndrome	Drug: Cannabidiol vaginal suppository;Drug: Placebo vaginal suppository	University of New Mexico	NULL	Withdrawn	18 Years	N/A	Female	0	Phase 1	United States

271. 強直性脊椎炎

臨床試験数 : 563 / 薬物数 : 372 - (DrugBank : 72) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-004226-15-DK (EUCTR)	26/10/2018	05/01/2018	Can-Art Effect and safety of using Canabis derivatives for the treatment of pain in patients with inflammatory Arthritis, such as reumatoid arthritis and ankylosing spondylitis, the latter being a type of arthritis that causes a long term inflammation of the joints of the spine. A randomized, double blinded, placebo controlled trial, i.e. in this drug trial, a control group is given a placebo while another group is given the Cannabis derivative being studied.	CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A randomized, double blinded, placebo controlled trial - Can-Art	Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) MedDRA version: 20.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Cannabidiol tablet 10 mg Other descriptive name: CANNABIDIOL Product Name: Dronabinol capsule 2.5. mg INN or Proposed INN: DRONABINOL	King Christian 10th Hospital for Rheumatology	NULL	Not Recruiting			Female: yes Male: yes	180	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Denmark

先頭へ